The combination of anti-PD-1 and anti-CTLA-4 antibodies appears to be associated with a potentially higher risk of myocarditis, as well as an increased likelihood of fatal outcomes compared to ICI monotherapy, while it remains unclear whether the risk is similarly elevated with the combination of chemotherapy and immunotherapy, given the limited data available (64–66). This evidence concerns the gene PDCD1 and myocarditis.